Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension

J Cardiovasc Pharmacol. 2024 Jun 1;83(6):612-620. doi: 10.1097/FJC.0000000000001557.

Abstract

Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance (PVR), imposing overload on the right ventricle (RV) and imbalance of the redox state. Our study investigated the influence of treatment with sulforaphane (SFN), found in cruciferous vegetables, on RV remodeling and redox homeostasis in monocrotaline (MCT)-induced PAH. Male Wistar rats were separated into 4 groups: control (CTR); CTR + SFN; MCT; and MCT + SFN. PAH induction was implemented by a single dose of MCT (60 mg/kg intraperitoneally). Treatment with SFN (2.5 mg/kg/day intraperitoneally) started on the seventh day after the MCT injection and persisted for 2 weeks. After 21 days of PAH induction, echocardiographic, hemodynamic, and oxidative stress evaluation was performed. The MCT group showed an increase in RV hypertrophy, RV systolic area, RV systolic, mean pulmonary artery pressure, and PVR and exhibited a decrease in the RV outflow tract acceleration time/ejection time ratio, RV fractional shortening, and tricuspid annular plane systolic excursion compared to CTR ( P < 0.05). SFN-treated PAH attenuated detrimental changes in tricuspid annular plane systolic excursion, mean pulmonary artery pressure, and PVR parameters. Catalase levels and the glutathione/Glutathione disulfide (GSSG) ratio were diminished in the MCT group compared to CTR ( P < 0.05). SFN increased catalase levels and normalized the glutathione/GSSG ratio to control levels ( P < 0.05). Data express the benefit of SFN treatment on the cardiac function of rats with PAH associated with the cellular redox state.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Arterial Pressure / drug effects
  • Disease Models, Animal*
  • Homeostasis / drug effects
  • Hypertension, Pulmonary / chemically induced
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / metabolism
  • Hypertension, Pulmonary / physiopathology
  • Hypertrophy, Right Ventricular / drug therapy
  • Hypertrophy, Right Ventricular / metabolism
  • Hypertrophy, Right Ventricular / physiopathology
  • Isothiocyanates* / pharmacology
  • Male
  • Monocrotaline*
  • Myocardial Contraction / drug effects
  • Oxidation-Reduction*
  • Oxidative Stress* / drug effects
  • Pulmonary Arterial Hypertension / drug therapy
  • Pulmonary Arterial Hypertension / metabolism
  • Pulmonary Arterial Hypertension / physiopathology
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / metabolism
  • Pulmonary Artery / physiopathology
  • Rats
  • Rats, Wistar*
  • Sulfoxides* / pharmacology
  • Ventricular Dysfunction, Right / drug therapy
  • Ventricular Dysfunction, Right / metabolism
  • Ventricular Dysfunction, Right / physiopathology
  • Ventricular Function, Right* / drug effects
  • Ventricular Remodeling / drug effects

Substances

  • sulforaphane
  • Sulfoxides
  • Isothiocyanates
  • Monocrotaline
  • Antioxidants